Lonza Welcomes New Group Chief Executive Officer Wolfgang Wienand

   Lonza Group AG / Key word(s): Personnel
   Lonza Welcomes New Group Chief Executive Officer Wolfgang Wienand
   01.07.2024 / 07:00 CET/CEST
     ____________________________________________________________

   
     * Wolfgang Wienand commences his tenure as Chief Executive
       Officer of Lonza Group
     * Albert M. Baehny will retire from Lonza Group following a
       transition period

   Basel, Switzerland, 1 July 2024 - Wolfgang Wienand joins Lonza
   Group today as Chief Executive Officer (CEO). Wolfgang succeeds
   Albert M. Baehny, who took on the role of CEO ad interim in
   October 2023 and was Chairman of the Board of Directors of Lonza
   from 2018 to May 2024. Albert will work with Wolfgang to ensure a
   smooth leadership handover before he retires from Lonza this
   summer.

   Jean-Marc Huët, Chairman of the Board of Directors, Lonza,
   commented: "On behalf of the Board, I extend a warm welcome to
   Wolfgang as he joins Lonza. Wolfgang brings with him a wealth of
   CDMO experience, combined with deep strategic and scientific
   expertise. As Wolfgang joins, we look forward to an era of stable
   and structured growth under his leadership."

   Wolfgang Wienand, Chief Executive Officer, Lonza, commented:
   "Having worked in the CDMO industry for almost two decades, I
   always had great respect for Lonza's ability to transform and
   grow at pace. It is a privilege to join this remarkable company
   as CEO. As I commence my journey with Lonza, we are embarking on
   a quest to meet and exceed the needs of our customers and their
   patients. I am greatly looking forward to working with the team
   to build on our strong foundations and create a strategy for us
   to deliver continued growth and reach our full potential."

   Since 2019, Wolfgang has held the role of CEO at Swiss CDMO,
   Siegfried. Wolfgang previously served as Chief Scientific Officer
   and then as Chief Strategy Officer in Siegfried's executive
   leadership team. Prior to joining Siegfried in 2010, Wolfgang
   held a series of positions with increasing seniority at the
   German specialty chemicals company Evonik Industries.

About Lonza

   Lonza is one of the world's largest healthcare manufacturing
   organizations. Working across five continents, our global
   community of around 18,000 colleagues helps pharmaceutical,
   biotech and nutrition companies to bring their treatments to
   market. United by our vision to bring any therapy to life, we
   support our customers with a combination of technological
   insight, world-class manufacturing, scientific expertise, process
   excellence and innovation. Our work enables our customers to
   develop and commercialize their therapeutic discoveries, allowing
   their patients to benefit from life-saving and life-enhancing
   treatments.

   Our business is structured to meet our customers' complex needs
   across four divisions: Biologics, Small Molecules, Cell & Gene,
   and Capsules & Health Ingredients. Our company generated sales of
   CHF 6.7 billion with a CORE EBITDA of CHF 2.0 billion in
   Full-Year 2023. Find out more at www.lonza.com

   Follow @Lonza on LinkedIn
   Follow @LonzaGroup on X

Lonza Contact Details

   Victoria Morgan
   Head of External Communications
   Lonza Group Ltd
   Tel +41 61 316 2283
   victoria.morgan@lonza.com

   Daniel Buchta
   Investor Relations
   Lonza Group Ltd
   Tel +41 61 316 2985
   daniel.buchta@lonza.com

   Additional Information and Disclaimer
   Lonza Group Ltd has its headquarters in Basel, Switzerland, and
   is listed on the SIX Swiss Exchange. It has a secondary listing
   on the Singapore Exchange Securities Trading Limited ("SGX-ST").
   Lonza Group Ltd is not subject to the SGX-ST's continuing listing
   requirements but remains subject to Rules 217 and 751 of the
   SGX-ST Listing Manual.

   Certain matters discussed in this news release may constitute
   forward-looking statements. These statements are based on current
   expectations and estimates of Lonza Group Ltd, although Lonza
   Group Ltd can give no assurance that these expectations and
   estimates will be achieved. Investors are cautioned that all
   forward-looking statements involve risks and uncertainty and are
   qualified in their entirety. The actual results may differ
   materially in the future from the forward-looking statements
   included in this news release due to various factors.
   Furthermore, except as otherwise required by law, Lonza Group Ltd
   disclaims any intention or obligation to update the statements
   contained in this news release.

   All trademarks belong to Lonza and are registered in CH, US
   and/or EU, or belong to their respective third-party owners and
   are used only for informational purposes.

Privacy Policy link

To immediately delete all the data

____________________________________________________________

   End of Media Release
     ____________________________________________________________

   Language:    English
   Company:     Lonza Group AG
                Münchensteinerstrasse 38
                4052 Basel
                Switzerland
   Phone:       +4161 316 81 11
   Internet:    www.lonza.com
   ISIN:        CH0013841017
   Valor:       1384101
   Listed:      SIX Swiss Exchange
   EQS News ID: 1935935

   End of News EQS News Service
     ____________________________________________________________

1935935 01.07.2024 CET/CEST